Published on 24/12/2025
ClinicalTrials.gov vs. EudraCT: What Sponsors Need to Know
Introduction: Why Understanding Both Registries Matters
With globalization of clinical trials, it’s common for sponsors to run multi-country studies that span both the United States and the European Union. This dual footprint necessitates registration in both ClinicalTrials.gov (administered by the U.S. National Library of Medicine) and EudraCT (administered by the European Medicines Agency). Each registry has its own process, data fields, compliance timelines, and posting obligations.
Non-compliance in either registry can result in severe consequences: FDA monetary penalties in the U.S. and EMA inspection findings in the EU. This tutorial unpacks the core differences between the two systems, helping sponsors align registry activities with global transparency standards and regulatory expectations.
Overview of Each Registry System
| Feature | ClinicalTrials.gov | EudraCT |
|---|---|---|
| Administered By | U.S. National Library of Medicine (NLM) | European Medicines Agency (EMA) |
| Primary Legislation | FDAAA 801 / Final Rule | EU Clinical Trials Directive / Regulation (EU) 536/2014 |
| Unique Identifier | NCT Number | EudraCT Number |
| Result Disclosure Timeline | 12 months post primary completion | 12 months post last subject visit (EU-specific) |
| Result Publicity | Publicly available via PRS | Published on EU Clinical Trials Register |
Registration Process: PRS vs EudraCT Portal
The registration workflow differs substantially:
- ClinicalTrials.gov: Sponsors create a Protocol Registration and Results System (PRS) account. After login, trial data is
EudraCT often requires internal coordination across regulatory, clinical, and quality teams, especially when trials are conducted across multiple EU countries.
Data Fields and Requirements: Comparing Depth and Structure
While both systems capture essential protocol details, there are key differences:
- ClinicalTrials.gov focuses on outcome measures, adverse events, and statistical analysis summary. Mandatory fields are defined under the Final Rule with results entry in tabular format.
- EudraCT includes IMP-specific data (Investigational Medicinal Products), country-wise ethical submissions, and regulatory risk management information not captured in CT.gov.
For example, EudraCT may ask about placebo comparators, device usage, or additional pediatric annexes. The result format is also different — EudraCT requires structured summary results in a predefined XML schema.
Global Trial Disclosure and Dual Obligations
Global trials must often comply with ICMJE (International Committee of Medical Journal Editors) policy, which requires pre-trial registration in a recognized database. For trials run in both the US and EU:
- Register in both ClinicalTrials.gov and EudraCT
- Ensure consistency in fields like sponsor name, start date, primary outcome measure, and status
- Monitor disclosure timelines – different trigger points exist (e.g., “primary completion date” in CT.gov vs. “last subject visit” in EudraCT)
Visit PharmaGMP.in for detailed trial management SOPs and registry compliance checklists.
Result Posting and Public Access
One of the most critical differences lies in how trial results are posted and accessed by the public:
- ClinicalTrials.gov: Sponsors must upload structured summary results, including participant flow, baseline characteristics, outcome measures, and adverse event tables. These are visible within 30 days after quality control review.
- EudraCT: Summary results are uploaded via XML and reviewed by EMA. Once validated, results appear on the EU Clinical Trials Register.
Additionally, ClinicalTrials.gov provides a history of updates and changes, improving transparency. EudraCT entries, on the other hand, are more static, with fewer historical revisions displayed publicly.
Regulatory Penalties for Non-Compliance
Compliance is not optional. Regulatory authorities take registry failures seriously:
- FDA: Under 42 CFR Part 11, sponsors may face civil monetary penalties up to $13,000/day for late result reporting.
- EMA: May issue findings during Good Clinical Practice (GCP) inspections and delay marketing authorization due to missing transparency obligations.
For multinational trials, discrepancies between CT.gov and EudraCT can raise red flags during inspections. QA teams should proactively review registry entries before audits. Sponsors are advised to maintain SOPs for registry tracking, updates, and version control.
Transition to CTIS and the Future of Trial Registries
As the EU transitions from EudraCT to the Clinical Trials Information System (CTIS), sponsors must prepare for further harmonization. CTIS will unify registration, ethical review, and result posting across all EU member states under a single platform. However, EudraCT remains active for legacy trials approved before the full CTIS implementation.
Key action points for sponsors:
- Assess which trials need dual registration (EudraCT + ClinicalTrials.gov)
- Identify trials transitioning to CTIS
- Update SOPs to reflect CTIS processes and integration points
Explore CTIS-readiness tools at PharmaValidation.in or follow EU updates at EMA.
Conclusion
Registering clinical trials in both ClinicalTrials.gov and EudraCT requires a deep understanding of registry-specific processes, timelines, and data requirements. Each registry serves different regulatory mandates but together ensure trial transparency on a global scale. Sponsors should build cross-functional alignment between regulatory, clinical, QA, and IT to ensure compliance and avoid regulatory setbacks.
By maintaining harmonized entries, following update schedules, and preparing for CTIS migration, organizations can demonstrate their commitment to ethical trial conduct and global public health transparency. For practical guidance on registry planning, you may refer to the ICH’s quality guidelines or consult global clinical operations experts at ClinicalStudies.in.